Esperion Therapeutics ESPR Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$25.2M+37.7% | —— | -$31.33M-6.1% | -$12.73M+79.5% | -$40.46M-166% | ||
| $27K+3.8% | $26K-3.7% | $26K0.0% | $27K+170% | $26K— | ||
| $2.5M+1.5% | $2.39M-14.9% | $2.35M-22.3% | $2.67M-8.9% | $2.47M-23.8% | ||
| $589K-15.7% | $641K+273% | $847K+89.5% | $820K+85.5% | $699K+60.0% | ||
| -$7.84M-780% | $21.21M+72.2% | $11.23M+50.5% | $26.45M+360% | $1.15M-81.2% | ||
| -$915K-119% | —— | —— | $15.14M+33.1% | $4.83M-35.3% | ||
| $3.34M-88.0% | —— | $2.9M— | $2.62M-86.5% | $27.84M+907% | ||
| -$4.86M-422% | $12.72M+100% | $21.18M+63.2% | -$1.75M-254% | -$932K+56.1% | ||
| $17.34M+252% | $8.91M+141% | $6.18M+56.9% | $10.79M— | $4.93M-25.3% | ||
| $9.05M+328% | $3.8M+158% | $8.37M+250% | $17.77M+305% | -$3.98M-201% | ||
| -$27.72M-22.5% | —— | -$4.29M— | -$31.42M— | -$22.63M-142% | ||
| $189K— | $0— | $0-100% | $0-100% | $0-100% | ||
| -$189K— | $0— | $0+100% | $0+100% | $0+100% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| —— | $61K+741% | $61K+741% | $61K+741% | $61K+741% | ||
| $16.22M+316% | $30.16M-13.8% | $10.67M— | $2.85M— | -$7.5M-108% | ||
| -$11.69M+61.2% | $75.41M+171,275% | $6.39M— | -$28.57M— | -$30.13M-121% | ||
| —— | $4.07M+43.4% | $4.07M+43.4% | $4.07M+43.4% | $4.07M+43.4% | ||
| —— | $153K— | $153K— | $153K— | $153K— | ||
| $589K-15.7% | $641K+273% | $847K+89.5% | $820K+85.5% | $699K+60.0% | ||
| $27K+3.8% | $26K-3.7% | $26K0.0% | $27K+170% | $26K— | ||
| $9.05M+328% | —— | —— | —— | -$3.98M— | ||
| -$4.86M-422% | $12.72M+100% | $21.18M+63.2% | -$1.75M-254% | -$932K+56.1% | ||
| $17.34M+252% | $8.91M+141% | $6.18M+56.9% | $10.79M— | $4.93M-25.3% | ||
| $13.89M+6.1% | $16.21M+27.9% | $14.64M+22.1% | $13.27M— | $13.09M— | ||
| $18.48M+76.3% | $14.64M+51.1% | $16.36M+84.6% | $13.58M+80.3% | $10.48M— | ||
| $0-100% | —— | —— | —— | $7.5M— | ||
| —— | $18.15M-19.9% | $18.15M-19.9% | $18.15M-19.9% | $18.15M-19.9% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| —— | $61K+741% | $61K+741% | $61K+741% | $61K+741% | ||
| $16.22M— | $10.35M— | $0— | $0-100% | $0-100% | ||
| —— | $13.73M-73.9% | $13.73M-73.9% | $13.73M-73.9% | $13.73M-73.9% | ||
| —— | $153K— | $153K— | $153K— | $153K— | ||
| $27K-10.0% | $8K-55.6% | $9K— | —— | $30K-58.3% | ||
| -$27.91M-23.3% | —— | -$4.29M— | -$31.42M— | -$22.63M-142% | ||
| -$27.91M-23.3% | —— | -$4.29M— | -$31.42M— | -$22.63M-142% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Esperion Therapeutics generate?
- Esperion Therapeutics (ESPR) generated -$86.1M in operating cash flow over the trailing twelve months.
- What is Esperion Therapeutics's free cash flow?
- After $189.0K of capital expenditures, Esperion Therapeutics's free cash flow was -$86.2M over the trailing twelve months, down 129.5% year over year.
- Where does Esperion Therapeutics's cash flow data come from?
- Every line is extracted from Esperion Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
